Pulse Biosciences announces treatment of first patients in NPS study
Pulse Biosciences, Inc. announced treatment of the first patients in its multicenter study to evaluate the safety and efficacy of its Nano-Pulse Stimulation technology for eliminating Sebaceous Hyperplasia, an unsightly benign skin lesion that typically appears on facial skin and is considered a difficult-to-treat condition with current modalities. NPS is a non-thermal technology that utilizes ultra-short, nanosecond pulsed electrical fields to directly affect cell membranes and intracellular structures while sparing non-cellular tissues. A previously published study of NPS in the treatment of seborrheic keratosis skin lesions in 58 patients provided the first human evidence that NPS' mechanism of action is well suited to target a broad range of difficult-to-treat benign and non-benign skin lesions by targeting the cellular structures of lesions, while sparing the surrounding non-cellular tissue of the dermal layer of skin. The sparing of surrounding non-cellular skin tissues enables the treatment of deeper cellular structures in the skin such as the sebaceous glands that cause SH lesions.